Effect | Mean change from baseline | |
---|---|---|
 | Pioglitazone | Placebo |
Change in HbA1c in year 1 (%-points) | -0.9 | -0.3 |
Change in HbA1c in year 2 (%-points) | +0.1 | +0.1 |
Change in HbA1c in year 3 (%-points) | +0.3 | +0.2 |
Change in subsequent years | +0.15 | +0.15 |
Total cholesterol (mmol/l) | +0.39 | +0.25 |
HDL-C (mmol/l) | +0.54 | +0.30 |
LDL-C (mmol/l) | +0.35 | +0.22 |
Triglycerides (mmol/l) | -0.064 | +0.076 |
Systolic blood pressure (mmHg) | -3.8 | -2.4 |
BMI (kg.m-2) | +1.1 | -0.1 |
Overall hypoglycaemic event rate (per 100 patient years)* | +9.29 | +6.68 |